PureTech Health PLC
LSE:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
LSE:PRTC
Watchlist
Price: 154.6 GBX -3.25% Market Closed
Market Cap: 370.1m GBX
Have any thoughts about
PureTech Health PLC?
Write Note

PureTech Health PLC
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PureTech Health PLC
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
PureTech Health PLC
LSE:PRTC
Long-Term Investments
$321m
CAGR 3-Years
-15%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Investments
$267m
CAGR 3-Years
-1%
CAGR 5-Years
15%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Investments
$4.8B
CAGR 3-Years
410%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Investments
$8.5B
CAGR 3-Years
14%
CAGR 5-Years
22%
CAGR 10-Years
34%
No Stocks Found

PureTech Health PLC
Glance View

Market Cap
370.1m GBX
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
37.96 GBX
Overvaluation 75%
Intrinsic Value
Price

See Also

What is PureTech Health PLC's Long-Term Investments?
Long-Term Investments
321m USD

Based on the financial report for Dec 31, 2023, PureTech Health PLC's Long-Term Investments amounts to 321m USD.

What is PureTech Health PLC's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
14%

Over the last year, the Long-Term Investments growth was 23%. The average annual Long-Term Investments growth rates for PureTech Health PLC have been -15% over the past three years , 14% over the past five years .

Back to Top